In honor of his 35-year career and commitment to blood cell research, Boston Children’s Hospital presented Orkin with the 2015 Lifetime Impact Award, during Boston Children’s Global Pediatric Innovation Summit held this week. The award recognizes a clinician and/or researcher who has significantly impacted pediatric care through practice-changing innovations or discoveries and made extraordinary and sustained leadership contributions in health care throughout his or her career.
The walls of Anne Hansen’s office tell a story. The main character, medical director of the Neonatal Intensive Care Unit at Boston Children’s Hospital, is an innovator, a global citizen and respected neonatologist. Her life and work has benefitted newborns and parents, medical trainees and colleagues around the world.
Read more about her life, work and innovations by hovering over the objects that surround her every day.
Stepping into Dr. Jean Connor’s office, the first thing you notice is color. So much color. Bella, Connor’s 9-year-old daughter, has decorated the space with handmade inspirational signs and artwork that explode with vibrant energy. “That’s how I innovate,” says Connor. “I like having all that positive energy around me.”
Connor, who has her PhD in nursing, directs nursing research at the Boston Children’s Heart Center. She was the first nurse to complete her post-doc at the Harvard School of Public Health and received a Champions in Healthcare award from the Boston Business Journal in 2012. Connor’s work translates industry research into actionable lessons and innovations that improve care at the bedside. In 2009, she developed a nursing acuity measurement tool called CAMEO (Complexity Assessment and Monitoring to Ensure Optimal Outcomes) that has since been validated to measure nursing workload across all pediatric and neonatal settings in the United States.
“I absolutely love my job,” Connor says. “I never thought I’d leave the bedside, but I feel like I’m impacting what happens at the bedside. We each have our ability to contribute to make the best possible experience for patients and families.”
Scroll over the items around Dr. Connor’s office to learn more about what inspires her.
“It’s all about the patients,” says Katherine Janeway, MD, when asked about the motivations behind her efforts to bring precision medicine to pediatric oncology. But it’s more than that; the drive to combine science and care is in her blood. A solid tumor specialist and cancer genomics researcher at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Janeway is the sixth generation of her family to choose a scientific or medical path—not just as a career, but also as a form of service.
Ken Mandl, MD, MPH, director of the Boston Children’s Hospital Computational Health Informatics Program, is used to seeing the world through a different lens. In high school, he began clicking photographs with his camera and developing them in a darkroom in his basement. Now, he frames subjects through the lens of epidemiology and informatics—driving discovery and care transformation through big data, apps and large-scale federated research networks.
In my last post I explained the genetic testing process that led to my daughter Esmé receiving results of two mutations of unknown significance. One, on the gene PCDH19, was discovered in 2012 with the GeneDx infantile epilepsy panel. The other, on SCN8A, was found with whole exome sequencing, also through GeneDx, in 2014.
When we received the SCN8A result, I was fascinated by the notion that it would have been included in our original epilepsy panel had we only waited a handful of months. In fact, in the time since Esmé’s original test in 2012, almost 20 new genes have been added to the GeneDx Infantile Epilepsy panel.
Though Bruce Zetter, PhD, Charles Nowiszewski Professor of Cancer Biology in Boston Children’s Hospital’s Department of Surgery, has had a lifelong passion for science, he once toyed with an alternate career—as an actor. But he stuck with his love for science and pursued a career in academic medicine. Countless patients, students, business partners and mentees have benefitted from that decision.
Tests for detecting Ebola in the blood can take anywhere from 12 hours to four days to yield results. But a recent study published in The Lancet reveals that a new point-of-care test can accurately determine results in mere minutes—another step toward potentially controlling the spread of Ebola.
Nira Pollock, MD, PhD, senior author of the paper and associate medical director of the Infectious Diseases Diagnostic Laboratory at Boston Children’s Hospital, along with researchers from Harvard Medical School and Partners In Health, showed that a commercially developed rapid diagnostic test (RDT), called the Corgenix ReEBOV Antigen Rapid Test kit, was as sensitive as a conventional laboratory-based method used for clinical testing during the recent outbreak in Sierra Leone.
Why don’t these wounds close? Blame a perfect storm of diabetic complications, such as reduced blood flow, neuropathy and impaired signaling between cells. According to research by Denisa Wagner, PhD, of Boston Children’s Hospital’s Program in Cellular and Molecular Medicine, a poorly understood feature of our immune system’s neutrophils may be one more ingredient in the storm.